FDA Inspection 1051143 — Hybio Pharmaceutical Co. Ltd (Site 1)
The FDA completed an inspection of Hybio Pharmaceutical Co. Ltd (Site 1) on Mar 30, 2018 in Shenzhen. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI)
- End Date
- Mar 30, 2018
- Fiscal Year
- 2018
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Shenzhen (China)